CybinHELP
Recorded

Cybin Study result

Review the key takeaways and the transcript of this earnings call.

Period 0Duration53 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Helus Pharma Phase III APPROACH Topline Results. Before we get started today, I would like to remind everyone that certain statements in this presentation are forward-looking statements and are prospective in nature. In preparing these forward-looking statements, several assumptions were made by Helus, and there are risks that actual results obtained by the company will differ materially from these statements. The company cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. We refer current and potential investors to certain cautionary statements contained in the presentation and to the forward-looking information and risk factor sections of the company's annual information form and the most recently filed management's discussion and analysis available at sedarplus.ca and on EDGAR at sec.gov. Forward-looking statements represent the company's expectations as of November 16th, 2026.

Operator

Except as required by securities laws, the company does not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Presenting on today's call are Michael Halstead, Chief Executive Officer, and Amir Inamdar, Chief Medical Officer of Helus Pharma. As a reminder, this call is being recorded and will be available for replay on the company's website. I would now like to hand the conference over to Michael Halstead, Chief Executive Officer of Helus Pharma.

Michael HalsteadCEO

Good morning, everyone, and thank you for joining us. Today is a defining moment for our company and a major milestone in the development of HLP003. We are very pleased to report positive topline results from the APPROACH study evaluating 003 as an adjunctive treatment for major depressive disorder. This study achieved its primary endpoint and key secondary endpoint with an impressive treatment effect and a favorable safety and tolerability profile. Several elements of the dataset stand out. First, the antidepressant effect was both clinically meaningful and robust, demonstrating substantial improvement in patients who had an inadequate response to their previously prescribed antidepressant medication. A 7.6 MADRS improvement over placebo was observed at the primary endpoint of six weeks. Second, the treatment effect emerged rapidly, as early as day two, and was durable through 12 weeks following two administrations with a 7-point MADRS improvement over placebo.

Michael HalsteadCEO

Third, the response and remission rates are particularly impressive. In major depressive disorder, remission is the outcome clinicians and patients strive to achieve, and the proportion of patients reaching remission in this study underscores the potential clinical significance of these results. Finally, these efficacy outcomes were accompanied by a favorable safety and tolerability profile that was consistent with our prior studies. Taken together, we believe APPROACH demonstrates the type of efficacy, durability, and tolerability that could meaningfully differentiate 003 as a new and important adjunctive treatment option for patients living with depression. This is important, as depression is a highly prevalent condition with unmet needs. Approximately 22 million people are living with MDD in the U.S. Of the millions of people being treated for depression, approximately two-thirds of patients do not achieve remission with first-line treatment.

Michael HalsteadCEO

As a result, clinicians often add treatments on to standard of care to build on the partial response and help patients progress towards remission. Based on the APPROACH data results, we believe HLP003 has the potential to set a new benchmark in the adjunctive treatment of MDD. This is particularly apparent in light of the efficacy and tolerability limitations of the five currently approved adjunctive treatments for MDD. These are the atypical antipsychotics. These antipsychotic treatments offer a modest benefit and are associated with side effects, including weight gain, cardiometabolic dysfunction, and movement disorders. Therefore, there remains a clear need for medicines that can deliver rapid and meaningful efficacy while being well tolerated. With that, I'll turn the call over to Amir, who will review the results in more detail before we open the call for questions.

Amir InamdarChief Medical Officer

Thanks, Michael. We are very excited about these study results, given the significant unmet need in adjunctive treatment of MDD. I'll begin with the study design. This is a randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of HLP003 as an adjunctive treatment in adult patients with MDD. Patients enrolled in this study were on a stable background dose of an antidepressant and were randomized to receive two administrations of either 16 milligrams of HLP003 or inactive placebo. The first administration was on day one, and the second, three weeks after. Patients stayed on a stable background dose of their antidepressant medication for the entire duration of the study. The primary endpoint was mean change from baseline versus placebo on the MADRS total score at week six. The key secondary endpoint was mean change from baseline in the MADRS total score at week 12.

Amir InamdarChief Medical Officer

The study enrolled adults who met DSM-5 criteria for MDD and were symptomatic despite treatment with an adequately dosed antidepressant. Participants were required to have moderate to severe depressive symptoms, reflected by a MADRS score of at least 24 and a CGI score of at least four at both the screening and baseline, and were having an inadequate response to the current antidepressant treatment. Patients with treatment-resistant depression, psychotic disorders, bipolar disorder, clinically significant suicidality, substance use disorder, or recent psychedelic exposure were excluded. Turning to demographics and baseline characteristics. The treatment groups were well-balanced. The average age was about 45 years. The majority of participants were female, and the mean baseline MADRS score of approximately 33 reflected a population with moderate to severe depression. Let's now discuss the efficacy results. Treatment with HLP003 demonstrated rapid, robust, durable, and clinically meaningful antidepressant effects across multiple endpoints.

Amir InamdarChief Medical Officer

At the primary endpoint of week six, HLP003 demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms compared with placebo. The LS mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo. That is a 7.6-point placebo-adjusted reduction with a p-value of less than 0.0001 and an effect size of 0.65. Equally important, the treatment effect was sustained through week 12, the key secondary endpoint. Patients treated with HLP003 continued to demonstrate improvement, achieving a LS mean treatment difference of 7 points versus placebo, with a p-value of less than 0.0001, with an effect size of 0.58. The onset was rapid, with treatment effects emerging as early as day two. It was statistically significant and maintained at every subsequent assessment through week 12, supporting both the rapid and durable treatment benefit.

Amir InamdarChief Medical Officer

Beyond mean changes in symptoms, we also evaluated outcomes that are particularly meaningful to patients and clinicians, response and remission. At week 6, 56% of patients receiving HLP003 were responders. Response was defined as at least a 50% reduction in MADRS score. Through week 12, response rates remained robust, with 45% patients on 003 still having at least a 50% improvement. Even more notable were the remission rates. Approximately 51% of patients achieved remission at week six. We used the conventional definition of remission, which is a MADRS score of 10 or less. Remission rates remained high through week 12, with 40% of patients still in remission. Both response and remission were rapidly achieved, with half of the patients on 003 achieving a response and 39% of patients reaching remission as early as day two, the day after dosing. Remission is ultimately the goal of treatment.

Amir InamdarChief Medical Officer

These findings suggest that a substantial proportion of patients were not simply improving, but returning to a level of functioning associated with minimal depressive burden. This data is further supported by statistically significant results in the global assessment of clinical symptoms in this trial. The Clinical Global Impression Scale rates a clinician's overall assessment of illness and closely aligns with clinical practice. 003 demonstrated statistically significant improvements on CGI-S compared with placebo at both week six and week 12. While efficacy and durability are paramount, an equally important aspect of any treatment is the safety and tolerability profile. Let me walk you through the safety data from the study. 003 exhibited a favorable safety and tolerability profile. This table lists adverse events that were reported in at least 10% of the participants. Most adverse events were mild to moderate in intensity, occurred on and resolved on the day of dosing.

Amir InamdarChief Medical Officer

There were no unexpected safety findings observed in this study. There were three treatment-related serious adverse events reported with 003. One of these was a suicide attempt by a participant who was a non-responder to treatment. This attempt occurred 55 days after the participant received the second dose of 003. The participant was admitted to the hospital two days after an overdose of their background antidepressant medication and was subsequently discharged. While suicidality is a feature of depression, based on a comprehensive assessment of the APPROACH data, including the Columbia Suicide Severity Rating Scale, we did not observe a signal of suicidality, which would require statistical disproportionality, a clear temporal relationship between the drug and the event, and exclusion of potential confounding factors, among others.

Amir InamdarChief Medical Officer

In summary, these results demonstrate a rapid, robust, and durable antidepressant effect that was consistently reflected across symptom improvement, response, remission, and clinician-rated measures of disease severity. HLP003 was well tolerated, and most reported AEs mild to moderate and confined to the day of dosing. As a psychiatrist who has spent many years caring for patients, I believe these findings suggest the potential for HLP003 to become an important treatment option for patients with MDD and support our confidence as we continue to execute our phase III program. Michael, I'll turn the call back over to you.

Michael HalsteadCEO

Thank you, Amir. Looking ahead, we remain focused on disciplined execution and the continued advancement of the HLP003 program. The EMBRACE study, our second phase III efficacy study, is ongoing. We expect results from EMBRACE in the fourth quarter of next year. In addition, the EXTEND trial, our long-term extension study, is also ongoing. I would also note that HLP003 has received breakthrough therapy designation from FDA. We are very proud of the Helus team that made this achievement possible, and we thank the participants, investigators, and the clinical sites who participated in this study. The APPROACH study delivered what we believe are highly compelling results across efficacy, durability, and tolerability measures, and position HLP003 as a potential important option for the adjunctive treatment of MDD. We look forward to updating you on our progress in the months ahead. With that, operator, please open the line for questions.

Operator

To ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. In the interest of time, we ask that you please limit yourself to one question and one follow-up. Please stand by while we compile the Q&A roster. Our first question comes from Ritu Baral with TD Cowen.

Ritu BaralAnalyst

Your line is open. Good morning, guys, and congratulations on this data.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day